Get the Stockscreener App
3.14
1.26%
-0.04
Neximmune Inc stock is currently priced at $3.14, with a 24-hour trading volume of 10,477.
It has seen a -1.26% decreased in the last 24 hours and a -41.42% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.23 pivot point. If it approaches the $3.10 support level, significant changes may occur.
Previous Close:
$3.18
Open:
$3.13
24h Volume:
10,477
Market Cap:
$4.30M
Revenue:
-
Net Income/Loss:
$-43.88M
P/E Ratio:
-0.0658
EPS:
-47.75
Net Cash Flow:
$-37.00M
1W Performance:
-7.92%
1M Performance:
-41.42%
6M Performance:
-15.57%
1Y Performance:
+888.66%
1D Range:
$3.07
$3.20
52W Range:
$0.15
$28.69
Neximmune Inc Stock (NEXI) Company Profile
Name
Neximmune Inc
Sector
Industry
Phone
301 825 9810
Address
9119 Gaither Road, Gaithersburg
Neximmune Inc Stock (NEXI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-21 | Initiated | Raymond James | Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Mar-09-21 | Initiated | Cantor Fitzgerald | Overweight |
Neximmune Inc Stock (NEXI) Latest News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Benzinga
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Neximmune Inc Stock (NEXI) Financials Data
Neximmune Inc (NEXI) Net Income 2024
NEXI net income (TTM) was -$43.88 million for the quarter ending September 30, 2023, a +28.23% increase year-over-year.
Neximmune Inc (NEXI) Cash Flow 2024
NEXI recorded a free cash flow (TTM) of -$37.00 million for the quarter ending September 30, 2023, a +30.26% increase year-over-year.
Neximmune Inc (NEXI) Earnings per Share 2024
NEXI earnings per share (TTM) was -$42.12 for the quarter ending September 30, 2023, a +36.27% growth year-over-year.
Neximmune Inc Stock (NEXI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roemer Alan S. | Director |
Nov 21 '23 |
Sale |
2.16 |
3,833 |
8,287 |
3,992 |
About Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
1.66%
3.17%
Cap:
|
Volume (24h):